← All trials
NCT04877275
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 21, 2021
- Primary completion
- Dec 30, 2024
- Completion date
- Dec 30, 2024
- First posted
- May 7, 2021
- Last posted
- Jun 8, 2021
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Wuhan Union Hospital, ChinaLead sponsor
- Huazhong University of Science and TechnologySponsor investigator
- Huazhong University of Science and TechnologyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.